A Phase I Study of Donor BPX-501 T Cell Infusion for Adults with Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogenetic Transplant
This is a Phase I, multicenter, open-label, non-randomized study of BPX-501 T cell infusion in adults with hematological malignancies presenting with recurrent disease > 100 days post-allogeneic transplant or minimal residual disease (MRD) > 30 days post-allogeneic transplant.
Study Number: 

PH 285116

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.